Edwin Francis, Patel Tarun B
Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois 60153.
Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois 60153.
J Biol Chem. 2008 Feb 8;283(6):3181-3190. doi: 10.1074/jbc.M706567200. Epub 2007 Dec 10.
Sprouty (SPRY) proteins modulate receptor-tyrosine kinase signaling and, thereby, regulate cell migration and proliferation. Here, we have examined the role of endogenous human SPRY2 (hSPRY2) in the regulation of cellular apoptosis. Small inhibitory RNA-mediated silencing of hSPRY2 abolished the anti-apoptotic action of serum in adrenal cortex adenocarcinoma (SW13) cells. Silencing of hSPRY2 decreased serum- or epidermal growth factor (EGF)-elicited activation of AKT and ERK1/2 and reduced the levels of EGF receptor. Silencing of hSPRY2 also inhibited serum-induced activation of p90RSK and decreased phosphorylation of pro-apoptotic protein BAD (BCL2-antagonist of cell death) by p90RSK. Inhibiting both the ERK1/2 and AKT pathways abolished the ability of serum to protect against apoptosis, mimicking the effects of silencing hSPRY2. Serum transactivated the EGF receptor (EGFR), and inhibition of the EGFR by a neutralizing antibody attenuated the anti-apoptotic actions of serum. Consistent with the role of EGFR and perhaps other growth factor receptors in the anti-apoptotic actions of serum, the tyrosine kinase binding domain of c-Cbl (Cbl-TKB) protected against down-regulation of the growth factor receptors such as EGFR and preserved the anti-apoptotic actions of serum when hSpry2 was silenced. Additionally, silencing of Spry2 in c-Cbl null cells did not alter the ability of serum to promote cell survival. Moreover, reintroduction of wild type hSPRY2, but not its mutants that do not bind c-Cbl or CIN85 into SW13 cells after endogenous hSPRY2 had been silenced, restored the anti-apoptotic actions of serum. Overall, we conclude that endogenous hSPRY2-mediated regulation of apoptosis requires c-Cbl and is manifested by the ability of hSPRY2 to sequester c-Cbl and thereby augment signaling via growth factor receptors.
Sprouty(SPRY)蛋白可调节受体酪氨酸激酶信号传导,从而调控细胞迁移和增殖。在此,我们研究了内源性人SPRY2(hSPRY2)在细胞凋亡调控中的作用。小干扰RNA介导的hSPRY2沉默消除了血清对肾上腺皮质腺癌(SW13)细胞的抗凋亡作用。hSPRY2沉默降低了血清或表皮生长因子(EGF)诱导的AKT和ERK1/2激活,并降低了EGF受体水平。hSPRY2沉默还抑制了血清诱导的p90RSK激活,并减少了p90RSK对促凋亡蛋白BAD(细胞死亡的BCL2拮抗剂)的磷酸化作用。抑制ERK1/2和AKT两条信号通路消除了血清的抗凋亡能力,这与hSPRY2沉默的效果相似。血清可反式激活EGF受体(EGFR),而用中和抗体抑制EGFR可减弱血清的抗凋亡作用。与EGFR以及可能其他生长因子受体在血清抗凋亡作用中的作用一致,c-Cbl的酪氨酸激酶结合域(Cbl-TKB)可防止生长因子受体(如EGFR)下调,并在hSpry2沉默时保留血清的抗凋亡作用。此外,在c-Cbl基因缺失的细胞中沉默Spry2并不改变血清促进细胞存活的能力。而且,在内源性hSPRY2沉默后,将野生型hSPRY2(而非不与c-Cbl或CIN85结合的突变体)重新导入SW13细胞,可恢复血清的抗凋亡作用。总体而言,我们得出结论,内源性hSPRY2介导的凋亡调控需要c-Cbl,其表现为hSPRY2能够隔离c-Cbl,从而增强生长因子受体介导的信号传导。